Effective Sorafenib antileukemic activity has been consistently shown in FLT3‐ITD positive cell lines, indicating that FLT3 activating mutations are a crucial cause of AML, increasing the risk of recurrence and decreasing overall survival [13, 14]. The gene discussed is FLT3; the disease is acute myeloid leukemia.